Aim immunotech announces availability of the me/cfs clinical trial of its drug ampligen for enrollment to covid-19 ‘long haulers'

Institutional review board authorizes public notification for potential enrollment of subjects institutional review board authorizes public notification for potential enrollment of subjects

AIM Ratings Summary

AIM Quant Ranking